| Enrolling By Invitation | A Long-Term Study of Bivamelagon in Participants With Hypothalamic Obesity (HO) Hypothalamic Obesity | Phase 2 | 2025-11-10 |
| Recruiting | A Trial of Setmelanotide in Patients With Congenital Hypothalamic Obesity (Sub-study of NCT05774756) Hypothalamic Obesity, Multiple Pituitary Hormone Deficiency Genetic Form, Septo-Optic Dysplasia | Phase 3 | 2025-09-23 |
| Active Not Recruiting | A Study of Setmelanotide in Patients With Prader-Willi Syndrome Prader-Willi Syndrome, Obesity, Hyperphagia | Phase 2 | 2025-03-04 |
| Enrolling By Invitation | Open-Label Extension Study of Setmelanotide Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 3 | 2024-10-21 |
| Completed | A Study to Assess Efficacy and Safety of LB54640 in Patients With Hypothalamic Obesity Hypothalamic Obesity | Phase 2 | 2024-07-11 |
| Recruiting | A Study of RM-718 in Healthy Subjects and Patients With MC4R Pathway Impairment Hypothalamic Obesity, Prader-Willi Syndrome, PWS | Phase 1 / Phase 2 | 2024-03-05 |
| Active Not Recruiting | A Trial of Setmelanotide in Acquired Hypothalamic Obesity Hypothalamic Obesity | Phase 3 | 2023-04-26 |
| Completed | Setmelanotide in Pediatric Participants With Rare Genetic Diseases of Obesity Bardet-Biedl Syndrome, POMC Deficiency Obesity, PCSK1 Deficiency Obesity | Phase 3 | 2022-03-08 |
| Completed | Phase 3 Crossover Trial of Two Formulations of Setmelanotide in Participants With Specific Gene Defects in the Bardet-Biedl Syndrome, POMC Deficiency | Phase 3 | 2021-12-21 |
| Active Not Recruiting | EMANATE: A Study of Setmelanotide in Patients With Specific Gene Variants in the MC4R Pathway Obesity, Genetic Obesity | Phase 3 | 2021-12-10 |
| Completed | DAYBREAK: A Study of Setmelanotide in Participants With Specific Gene Variants in the Melanocortin-4 Receptor Genetic Obesity | Phase 2 | 2021-11-30 |
| Completed | Study of Setmelanotide Effects on QTc (Corrected QT) Interval in Healthy Participants Healthy | Phase 4 | 2021-08-05 |
| Completed | Open-Label Study of Setmelanotide in Hypothalamic Obesity Hypothalamic Obesity | Phase 2 | 2021-06-07 |
| Completed | A Phase 1 Study to Evaluate the Pharmacokinetics of Setmelanotide in Subjects With Varying Degrees of Renal Im Renal Insufficiency | Phase 1 | 2020-07-09 |
| Completed | An Observational,Prospective Natural History Study of Early-Onset Extreme Obesity Due to Bi-Allelic Loss-of-Fu POMC Deficiency Obesity, PCSK1 Deficiency Obesity, LEPR Deficiency Obesity | — | 2019-08-06 |
| Completed | Setmelanotide (RM-493), Melanocortin-4 Receptor (MC4R) Agonist, in Bardet-Biedl Syndrome (BBS) and Alström Syn Bardet Biedl Syndrome (BBS), Alström Syndrome (AS) | Phase 3 | 2018-11-23 |
| Completed | Long Term Extension Trial of Setmelanotide Obesity Associated With Defects in Leptin-melanocortin Pathway | Phase 2 / Phase 3 | 2018-07-15 |
| Completed | The TEMPO (Tracing the Effect of the MC4 Pathway in Obesity) Registry Genetic Forms of Extreme Obesity | — | 2018-04-15 |
| Completed | Setmelanotide for the Treatment of Leptin Receptor (LEPR) Deficiency Obesity Leptin Receptor Deficiency Obesity | Phase 3 | 2018-01-30 |
| Completed | Setmelanotide in a Single Patient With Partial Lipodystrophy Hypertriglyceridemia, Obesity | Phase 2 | 2017-08-15 |
| Completed | Setmelanotide for the Treatment of Early-Onset Pro-Opiomelanocortin (POMC) Deficiency Obesity Pro-opiomelanocortin (POMC) Deficiency Obesity | Phase 3 | 2017-02-14 |
| Completed | Setmelanotide Phase 2 Treatment Trial in Participants With Rare Genetic Disorders of Obesity Genetic Obesity, Obesity, Obesity Due to Melanocortin 4 Receptor Deficiency | Phase 2 | 2017-02-10 |
| Completed | Genetic Testing and Phenotypic Characterization of Severely Obese Pediatric and Adult Volunteers Pro-opiomelanocortin (POMC), Proprotein Convertase Subtilisin/Kexin Type 1 (PCSK1) and Leptin Receptor (LepR) Gene Mutations | — | 2016-09-28 |
| Completed | Phase 2 Trial to Evaluate Safety and Efficacy of Setmelanotide (RM-493) in Obese Participants With Prader-Will Prader-Willi Syndrome | Phase 2 | 2015-03-19 |
| Completed | Phase 1b/2a Study to Evaluate Safety and Efficacy of Setmelanotide in Obese Patients Overweight and Obesity | Phase 1 / Phase 2 | 2014-01-01 |
| Completed | Effects of RM-493 on Energy Expenditure in Obese Individuals Obesity, Morbid Obesity | Phase 1 | 2013-05-01 |
| Completed | Phase 2 Study to Evaluate Safety and Efficacy of RM-493 in Obese Participants Overweight | Phase 2 | 2013-01-14 |
| Completed | Study to Evaluate Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of RM-493 Administered to Health Overweight, Obese | Phase 1 | 2012-01-01 |
| Approved For Marketing | An Expanded Access Protocol for Setmelanotide for Treatment of Bardet-Biedl Syndrome (BBS) Bardet-Biedl Syndrome (BBS), Obesity | — | — |